Trump Fires Fed Governor Cook, Eli Lilly’s Weight Loss Pill & How to Not Get Replaced by AI
Prof G Markets
00:00
Eli Lilly's Game-Changing Obesity Drug Trial Results
This chapter explores the promising late-stage trial results of Eli Lilly's new oral obesity drug, Orpaglipron, aimed at those with type 2 diabetes. The conversation contrasts its convenience with injectable alternatives and discusses the drug's impact on the market and Eli Lilly's stock performance.
Transcript
Play full episode
